Cassava Sciences | PTIE - Net Income


Cassava Sciences reported $-10.33M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Abbott USD 928M 149M Jun/2026
Amgen USD 2.38B 556M Jun/2026
Biogen USD 97.5M 222M Jun/2026
Cara Therapeutics USD -6.8M 1.28M Mar/2026
Cassava Sciences USD -10.33M 2.21M Mar/2026
Eisai JPY 18.24B 21.49B Jun/2026
Eli Lilly USD 7.1B 301M Jun/2026
Geron USD -3.64M 27.5M Mar/2026
J&J USD 5.53B 299M Jun/2026
Merck USD -1.34B 2.9B Jun/2026
Novartis USD 3.26B 108M Jun/2026
Novavax USD 17.53M 219.91M Dec/2025
Pfizer USD -248M 2.94B Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026